Challenges for Better Diagnosis and Management of Pancreatic and Biliary Tract Cancers Focusing on Blood Biomarkers: A Systematic Review

Background: pancreatic cancer (PCa) and biliary tract cancer (BTC) are cancers with a poor prognosis and few effective treatments. One of the reasons for this is late detection. Many researchers are tackling to develop non-invasive biomarkers for cancer, but few are specific for PCa or BTC. In addit...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 13; no. 16; p. 4220
Main Authors Tominaga, Hiroto, Matsuzaki, Juntaro, Oikawa, Chihiro, Toyoshima, Kensho, Manabe, Haruki, Ozawa, Eriko, Shimamura, Atsushi, Yokoyama, Riko, Serizawa, Yusuke, Ochiya, Takahiro, Saito, Yoshimasa
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 23.08.2021
MDPI
Subjects
Antigens
Biliary tract
Biomarkers
Cancer therapies
Chemotherapy
Cholangiocarcinoma
Diagnosis
Fibroblasts
Lymphocytes
Medical prognosis
Metastasis
MicroRNAs
Neuroendocrine tumors
Pancreatic cancer
Plasma
Prognosis
Protein expression
Proteins
Review
Systematic review
Tumors
Asia
Online AccessGet full text
ISSN2072-6694
2072-6694
DOI10.3390/cancers13164220

Cover

Abstract Background: pancreatic cancer (PCa) and biliary tract cancer (BTC) are cancers with a poor prognosis and few effective treatments. One of the reasons for this is late detection. Many researchers are tackling to develop non-invasive biomarkers for cancer, but few are specific for PCa or BTC. In addition, genetic abnormalities occur in cancer tissues, which ultimately affect the expression of various molecules. Therefore, it is important to identify molecules that are altered in PCa and BTC. For this systematic review, a systematic review of Medline and Embase to select biomarker studies of PCa and BTC patients was conducted. Results: after reviewing 72 studies, 79 biomarker candidates were identified, including 22 nucleic acids, 43 proteins, and 14 immune cell types. Of the 72 studies, 61 examined PCa, and 11 examined BTC. Conclusion: PCa and BTC are characterized by nucleic acid, protein, and immune cell profiles that are markedly different from those of healthy subjects. These altered molecules and cell subsets may serve as cancer-specific biomarkers, particularly in blood. Further studies are needed to better understand the diagnosis and prognosis of PCa and BTC.
AbstractList Simple SummaryPancreatic and biliary tract cancers are malignant tumors that have a very poor prognosis and are resistant to chemotherapy. The later a cancer is detected, the worse the prognosis becomes; therefore, early detection is important. Biomarkers are physiological indices that serve as a guide to indicate the presence or absence of a certain disease, or its progression. The purpose of our research is to summarize previously reported biomarkers for the diagnosis and prognosis of pancreatic and biliary tract cancers. AbstractBackground: pancreatic cancer (PCa) and biliary tract cancer (BTC) are cancers with a poor prognosis and few effective treatments. One of the reasons for this is late detection. Many researchers are tackling to develop non-invasive biomarkers for cancer, but few are specific for PCa or BTC. In addition, genetic abnormalities occur in cancer tissues, which ultimately affect the expression of various molecules. Therefore, it is important to identify molecules that are altered in PCa and BTC. For this systematic review, a systematic review of Medline and Embase to select biomarker studies of PCa and BTC patients was conducted. Results: after reviewing 72 studies, 79 biomarker candidates were identified, including 22 nucleic acids, 43 proteins, and 14 immune cell types. Of the 72 studies, 61 examined PCa, and 11 examined BTC. Conclusion: PCa and BTC are characterized by nucleic acid, protein, and immune cell profiles that are markedly different from those of healthy subjects. These altered molecules and cell subsets may serve as cancer-specific biomarkers, particularly in blood. Further studies are needed to better understand the diagnosis and prognosis of PCa and BTC.
pancreatic cancer (PCa) and biliary tract cancer (BTC) are cancers with a poor prognosis and few effective treatments. One of the reasons for this is late detection. Many researchers are tackling to develop non-invasive biomarkers for cancer, but few are specific for PCa or BTC. In addition, genetic abnormalities occur in cancer tissues, which ultimately affect the expression of various molecules. Therefore, it is important to identify molecules that are altered in PCa and BTC. For this systematic review, a systematic review of Medline and Embase to select biomarker studies of PCa and BTC patients was conducted.BACKGROUNDpancreatic cancer (PCa) and biliary tract cancer (BTC) are cancers with a poor prognosis and few effective treatments. One of the reasons for this is late detection. Many researchers are tackling to develop non-invasive biomarkers for cancer, but few are specific for PCa or BTC. In addition, genetic abnormalities occur in cancer tissues, which ultimately affect the expression of various molecules. Therefore, it is important to identify molecules that are altered in PCa and BTC. For this systematic review, a systematic review of Medline and Embase to select biomarker studies of PCa and BTC patients was conducted.after reviewing 72 studies, 79 biomarker candidates were identified, including 22 nucleic acids, 43 proteins, and 14 immune cell types. Of the 72 studies, 61 examined PCa, and 11 examined BTC.RESULTSafter reviewing 72 studies, 79 biomarker candidates were identified, including 22 nucleic acids, 43 proteins, and 14 immune cell types. Of the 72 studies, 61 examined PCa, and 11 examined BTC.PCa and BTC are characterized by nucleic acid, protein, and immune cell profiles that are markedly different from those of healthy subjects. These altered molecules and cell subsets may serve as cancer-specific biomarkers, particularly in blood. Further studies are needed to better understand the diagnosis and prognosis of PCa and BTC.CONCLUSIONPCa and BTC are characterized by nucleic acid, protein, and immune cell profiles that are markedly different from those of healthy subjects. These altered molecules and cell subsets may serve as cancer-specific biomarkers, particularly in blood. Further studies are needed to better understand the diagnosis and prognosis of PCa and BTC.
Background: pancreatic cancer (PCa) and biliary tract cancer (BTC) are cancers with a poor prognosis and few effective treatments. One of the reasons for this is late detection. Many researchers are tackling to develop non-invasive biomarkers for cancer, but few are specific for PCa or BTC. In addition, genetic abnormalities occur in cancer tissues, which ultimately affect the expression of various molecules. Therefore, it is important to identify molecules that are altered in PCa and BTC. For this systematic review, a systematic review of Medline and Embase to select biomarker studies of PCa and BTC patients was conducted. Results: after reviewing 72 studies, 79 biomarker candidates were identified, including 22 nucleic acids, 43 proteins, and 14 immune cell types. Of the 72 studies, 61 examined PCa, and 11 examined BTC. Conclusion: PCa and BTC are characterized by nucleic acid, protein, and immune cell profiles that are markedly different from those of healthy subjects. These altered molecules and cell subsets may serve as cancer-specific biomarkers, particularly in blood. Further studies are needed to better understand the diagnosis and prognosis of PCa and BTC.
Author Manabe, Haruki
Yokoyama, Riko
Saito, Yoshimasa
Shimamura, Atsushi
Serizawa, Yusuke
Tominaga, Hiroto
Oikawa, Chihiro
Ochiya, Takahiro
Toyoshima, Kensho
Matsuzaki, Juntaro
Ozawa, Eriko
AuthorAffiliation 1 Division of Pharmacotherapeutics, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan; tominagahiroto@keio.jp (H.T.); 0808oocc@keio.jp (C.O.); toyoken724@keio.jp (K.T.); haruki.may19@keio.jp (H.M.); eriko.ozw@gmail.com (E.O.); btw.orz.321427@keio.jp (A.S.); rikoy@keio.jp (R.Y.); serizawa.y29@keio.jp (Y.S.)
2 Department of Molecular and Cellular Medicine, Institute of Medical Science, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan; tochiya@tokyo-med.ac.jp
AuthorAffiliation_xml – name: 1 Division of Pharmacotherapeutics, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan; tominagahiroto@keio.jp (H.T.); 0808oocc@keio.jp (C.O.); toyoken724@keio.jp (K.T.); haruki.may19@keio.jp (H.M.); eriko.ozw@gmail.com (E.O.); btw.orz.321427@keio.jp (A.S.); rikoy@keio.jp (R.Y.); serizawa.y29@keio.jp (Y.S.)
– name: 2 Department of Molecular and Cellular Medicine, Institute of Medical Science, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan; tochiya@tokyo-med.ac.jp
Author_xml – sequence: 1
  givenname: Hiroto
  surname: Tominaga
  fullname: Tominaga, Hiroto
– sequence: 2
  givenname: Juntaro
  orcidid: 0000-0002-3204-5049
  surname: Matsuzaki
  fullname: Matsuzaki, Juntaro
– sequence: 3
  givenname: Chihiro
  surname: Oikawa
  fullname: Oikawa, Chihiro
– sequence: 4
  givenname: Kensho
  surname: Toyoshima
  fullname: Toyoshima, Kensho
– sequence: 5
  givenname: Haruki
  surname: Manabe
  fullname: Manabe, Haruki
– sequence: 6
  givenname: Eriko
  surname: Ozawa
  fullname: Ozawa, Eriko
– sequence: 7
  givenname: Atsushi
  surname: Shimamura
  fullname: Shimamura, Atsushi
– sequence: 8
  givenname: Riko
  surname: Yokoyama
  fullname: Yokoyama, Riko
– sequence: 9
  givenname: Yusuke
  surname: Serizawa
  fullname: Serizawa, Yusuke
– sequence: 10
  givenname: Takahiro
  surname: Ochiya
  fullname: Ochiya, Takahiro
– sequence: 11
  givenname: Yoshimasa
  surname: Saito
  fullname: Saito, Yoshimasa
BookMark eNp1UVtrFDEUDlKxtfbZ14AvvqzNfXZ8ELqrVaGiaH0OmeyZaWomaZNMZf-BP9tMt4IueCAk8F3O-XKeooMQAyD0nJJXnLfk1JpgIWXKqRKMkUfoiJGGLZRqxcFf70N0kvM1qcU5bVTzBB1yIXjLm-UR-rW-Mt5DGCDjPia8glIg4bfODCFml7EJG_zJBDPACKHg2OMvtW0CU5y9B1fOO5O2-DIZW_B6NxM-j3bKLgw4BrzyMc68OJr0o4Kv8Rn-ts0FxnuTr3Dn4Ocz9Lg3PsPJw32Mvp-_u1x_WFx8fv9xfXaxsEKJsqhBrRKKS8ravpOikxQYE0RJ2zVCLZnlgqtNNx9KCQfeScmFbSWItu0EP0Zvdr43UzfCxtZQyXh9k1ydbqujcfpfJLgrPcQ7veStUIpWg5cPBineTpCLHl224L0JEKesmVSKCEmIrNQXe9TrOKVQ480s0dRaNpUldyybYs4Jem1dqT8T5_7Oa0r0vG69t-6qO93T_QnxP8VvUS-vWg
CitedBy_id crossref_primary_10_3389_fonc_2022_888462
Cites_doi 10.1158/2326-6066.CIR-18-0070
10.1016/j.jhep.2019.05.026
10.3389/fimmu.2019.00847
10.3389/fonc.2020.553536
10.7314/APJCP.2013.14.12.7529
10.1002/cam4.1087
10.1084/jem.20180749
10.1016/j.radonc.2015.07.003
10.1016/j.humpath.2016.07.015
10.1172/JCI127515
10.1038/s41586-020-2015-4
10.1097/CJI.0000000000000062
10.1007/s00262-017-2053-4
10.18632/oncotarget.7537
10.1016/j.canlet.2017.05.007
10.1007/s13577-015-0117-3
10.1158/1078-0432.CCR-19-0081
10.3390/cancers12010197
10.3322/caac.21660
10.1016/j.ctrv.2008.11.009
10.1038/nrclinonc.2009.127
10.1186/s12967-018-1562-z
10.1002/hep.31304
10.1038/s41419-020-03234-x
10.1136/jitc-2019-000367
10.1038/srep37606
10.1038/s41467-020-15979-2
10.1111/liv.12014
10.1038/s41598-020-78320-3
10.18632/oncotarget.8527
10.1007/s00280-017-3475-6
10.1097/MPA.0000000000001150
10.7150/thno.36276
10.1038/bjc.2015.366
10.7717/peerj.9736
10.1038/onc.2010.215
10.1038/nrgastro.2016.51
10.1111/nyas.14049
10.1186/s40425-016-0150-0
10.1200/JCO.2010.33.8020
10.1056/NEJMoa1200694
10.1016/j.annonc.2020.02.011
10.1158/2326-6066.CIR-18-0061
10.1007/s00432-020-03463-9
10.7150/thno.26650
10.1158/0008-5472.CAN-17-2415
10.3892/ol.2012.784
10.1136/gutjnl-2016-312078
10.1038/nm.4123
10.1186/s13046-019-1477-4
10.1126/scitranslmed.aau9240
10.1097/CJI.0b013e31829fb7a2
10.1158/0008-5472.CAN-17-3876
10.1016/j.cell.2007.04.040
10.1038/s41598-017-06137-8
10.1016/j.celrep.2019.07.059
10.1093/jnci/djw283
10.1016/j.surg.2015.04.043
10.1158/1078-0432.CCR-20-0395
10.1186/s40425-019-0786-7
10.1097/01.sla.0000251366.62632.d3
10.3389/fimmu.2018.00814
10.1158/2326-6066.CIR-18-0448
10.1002/cam4.2583
10.1186/s13046-016-0406-z
10.1016/j.ymthe.2020.01.003
10.1186/s12885-018-4006-5
10.3389/fcell.2020.606817
10.1126/scitranslmed.aak9679
10.1038/onc.2017.209
10.1186/s40425-019-0554-8
10.1158/0008-5472.CAN-08-2023
10.1159/000447302
10.1158/0008-5472.CAN-16-1201
10.1097/CJI.0b013e3181eec14c
10.1038/nrgastro.2015.215
10.1186/s13045-019-0822-6
10.1038/s41388-020-1186-7
10.3390/cells8040320
10.1080/08820139.2019.1566356
10.1007/s00262-019-02398-6
10.21037/jgo-20-203
10.1200/JCO.2012.41.5984
ContentType Journal Article
Copyright 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2021 by the authors. 2021
Copyright_xml – notice: 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2021 by the authors. 2021
DBID AAYXX
CITATION
3V.
7T5
7TO
7XB
8FE
8FH
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
GUQSH
H94
HCIFZ
LK8
M2O
M7P
MBDVC
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOI 10.3390/cancers13164220
DatabaseName CrossRef
ProQuest Central (Corporate)
Immunology Abstracts
Oncogenes and Growth Factors Abstracts
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
ProQuest Central Student
ProQuest Research Library
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Biological Science Collection
Research Library
Biological Science Database
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Biological Science Database
ProQuest SciTech Collection
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2072-6694
ExternalDocumentID PMC8394661
10_3390_cancers13164220
GeographicLocations Asia
GeographicLocations_xml – name: Asia
GroupedDBID ---
53G
5VS
8FE
8FH
8G5
AADQD
AAFWJ
AAYXX
ABDBF
ABUWG
ACUHS
ADBBV
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
CITATION
DIK
DWQXO
E3Z
EBD
ESX
GNUQQ
GUQSH
GX1
HCIFZ
HYE
IAO
IHR
ITC
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
OK1
P6G
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RPM
TUS
3V.
7T5
7TO
7XB
8FK
H94
MBDVC
PKEHL
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c464t-422c64635129fb54b51e224065cb74682c3436db36db1103e3b5534c95e499b43
IEDL.DBID BENPR
ISSN 2072-6694
IngestDate Thu Aug 21 14:00:07 EDT 2025
Fri Sep 05 12:16:51 EDT 2025
Fri Jul 25 11:57:06 EDT 2025
Tue Jul 01 01:28:00 EDT 2025
Thu Apr 24 23:12:45 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 16
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c464t-422c64635129fb54b51e224065cb74682c3436db36db1103e3b5534c95e499b43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-3204-5049
OpenAccessLink https://www.proquest.com/docview/2564777787?pq-origsite=%requestingapplication%
PMID 34439378
PQID 2564777787
PQPubID 2032421
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8394661
proquest_miscellaneous_2566045005
proquest_journals_2564777787
crossref_citationtrail_10_3390_cancers13164220
crossref_primary_10_3390_cancers13164220
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20210823
PublicationDateYYYYMMDD 2021-08-23
PublicationDate_xml – month: 8
  year: 2021
  text: 20210823
  day: 23
PublicationDecade 2020
PublicationPlace Basel
PublicationPlace_xml – name: Basel
PublicationTitle Cancers
PublicationYear 2021
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Osborne (ref_41) 2019; 68
Yuan (ref_62) 2016; 4
Imamura (ref_14) 2017; 7
Moral (ref_64) 2020; 579
Banales (ref_4) 2016; 13
Liu (ref_54) 2017; 36
Jiang (ref_33) 2016; 22
Thakur (ref_49) 2018; 16
ref_18
Peng (ref_19) 2019; 8
Jiao (ref_58) 2021; 12
Liu (ref_87) 2020; 31
Waters (ref_85) 2015; 158
Li (ref_59) 2019; 38
Le (ref_68) 2013; 36
Feng (ref_55) 2020; 8
Zaidi (ref_44) 2019; 1445
Panni (ref_34) 2019; 11
Lu (ref_60) 2019; 9
Baumann (ref_69) 2020; 11
Brahmer (ref_75) 2012; 366
Jing (ref_53) 2019; 7
Wang (ref_20) 2012; 4
Zhang (ref_67) 2017; 66
Merz (ref_21) 2020; 26
Bengsch (ref_71) 2017; 66
Sergeant (ref_81) 2009; 6
Wang (ref_5) 2013; 31
Wang (ref_6) 2011; 29
Pan (ref_32) 2019; 12
Ye (ref_12) 2020; 2020
Cunningham (ref_8) 2007; 245
Quaranta (ref_36) 2018; 78
Lu (ref_35) 2017; 109
Brooks (ref_72) 2017; 78
Imai (ref_29) 2017; 6
Phua (ref_24) 2018; 81
Liu (ref_37) 2019; 216
Kanaya (ref_40) 2020; 28
Long (ref_13) 2017; 84
Liu (ref_30) 2020; 10
Griveau (ref_48) 2016; 7
Lim (ref_73) 2015; 117
Ma (ref_79) 2019; 7
Goto (ref_15) 2018; 18
Burrack (ref_76) 2019; 28
Prasad (ref_84) 2016; 7
Seifert (ref_63) 2020; 39
Umebayashi (ref_46) 2014; 34
Royal (ref_74) 2010; 33
Chaudhary (ref_17) 2017; 402
ref_77
Ireland (ref_23) 2016; 76
Tsukasa (ref_50) 2015; 28
Ali (ref_11) 2010; 3
Qi (ref_51) 2020; 8
Zhang (ref_39) 2019; 48
Shen (ref_57) 2013; 33
Hou (ref_26) 2021; 147
Anderson (ref_7) 2009; 35
Song (ref_10) 2013; 14
Li (ref_25) 2016; 57
Deng (ref_16) 2020; 8
Gorchs (ref_28) 2019; 10
Seo (ref_61) 2019; 25
Landgraf (ref_86) 2007; 129
Jansen (ref_3) 2020; 11
Zhou (ref_52) 2019; 71
Zhang (ref_56) 2021; 73
Seufferlein (ref_2) 2016; 13
Xu (ref_22) 2016; 35
Christmas (ref_65) 2018; 6
Sung (ref_1) 2021; 71
Bowden (ref_27) 2018; 47
Singh (ref_82) 2010; 29
Liu (ref_42) 2016; 6
Oberg (ref_43) 2018; 9
Soares (ref_38) 2015; 38
Takahashi (ref_47) 2020; 10
Sharma (ref_78) 2020; 130
Dieckmann (ref_45) 2012; 319
Patel (ref_66) 2019; 7
Fan (ref_31) 2018; 8
Stromnes (ref_70) 2019; 7
Dallas (ref_83) 2009; 69
Allen (ref_80) 2017; 9
Miyamae (ref_9) 2015; 113
References_xml – volume: 6
  start-page: 1561
  year: 2018
  ident: ref_65
  article-title: Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-18-0070
– volume: 71
  start-page: 753
  year: 2019
  ident: ref_52
  article-title: Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune check-point molecules
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2019.05.026
– volume: 10
  start-page: 847
  year: 2019
  ident: ref_28
  article-title: Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4(+) and CD8(+) T-Cells
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2019.00847
– volume: 10
  start-page: 553536
  year: 2020
  ident: ref_30
  article-title: Identification of Spindle and Kinetochore-Associated Family Genes as Therapeutic Targets and Prognostic Biomarkers in Pancreas Ductal Adenocarcinoma Microenvironment
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2020.553536
– volume: 14
  start-page: 7529
  year: 2013
  ident: ref_10
  article-title: MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells
  publication-title: Asian Pac. J. Cancer Prev.
  doi: 10.7314/APJCP.2013.14.12.7529
– volume: 6
  start-page: 1614
  year: 2017
  ident: ref_29
  article-title: The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer
  publication-title: Cancer Med.
  doi: 10.1002/cam4.1087
– volume: 34
  start-page: 4509
  year: 2014
  ident: ref_46
  article-title: An epithelial cell adhesion molecule- and CD3-bispecific antibody plus activated T-cells can eradicate chemo-resistant cancer stem-like pancreatic carcinoma cells in vitro
  publication-title: Anticancer. Res.
– volume: 216
  start-page: 656
  year: 2019
  ident: ref_37
  article-title: Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20180749
– volume: 117
  start-page: 165
  year: 2015
  ident: ref_73
  article-title: High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prog-nostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy
  publication-title: Radiother. Oncol.
  doi: 10.1016/j.radonc.2015.07.003
– volume: 57
  start-page: 182
  year: 2016
  ident: ref_25
  article-title: Overexpression of DIXDC1 correlates with enhanced cell growth and poor prognosis in human pancreatic ductal adenocarcinoma
  publication-title: Hum. Pathol.
  doi: 10.1016/j.humpath.2016.07.015
– volume: 130
  start-page: 451
  year: 2020
  ident: ref_78
  article-title: Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI127515
– volume: 579
  start-page: 130
  year: 2020
  ident: ref_64
  article-title: ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity
  publication-title: Nature
  doi: 10.1038/s41586-020-2015-4
– volume: 38
  start-page: 1
  year: 2015
  ident: ref_38
  article-title: PD-1/PD-L1 blockade together with vaccine therapy facilitates effector t-cell infiltration into pancreatic tumors
  publication-title: J. Immunother.
  doi: 10.1097/CJI.0000000000000062
– volume: 66
  start-page: 1609
  year: 2017
  ident: ref_71
  article-title: CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-017-2053-4
– volume: 7
  start-page: 13182
  year: 2016
  ident: ref_84
  article-title: Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.7537
– volume: 402
  start-page: 1
  year: 2017
  ident: ref_17
  article-title: Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of mi-croRNA-205
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2017.05.007
– volume: 28
  start-page: 167
  year: 2015
  ident: ref_50
  article-title: Slug contributes to gemcitabine resistance through epithelial-mesenchymal transition in CD133(+) pancreatic cancer cells
  publication-title: Hum. Cell
  doi: 10.1007/s13577-015-0117-3
– volume: 25
  start-page: 3934
  year: 2019
  ident: ref_61
  article-title: Mobilization of CD8(+) T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-19-0081
– ident: ref_18
  doi: 10.3390/cancers12010197
– volume: 71
  start-page: 209
  year: 2021
  ident: ref_1
  article-title: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21660
– volume: 35
  start-page: 322
  year: 2009
  ident: ref_7
  article-title: Adjuvant therapy for resected extrahepatic cholangiocarcinoma: A review of the literature and future directions
  publication-title: Cancer Treat. Rev.
  doi: 10.1016/j.ctrv.2008.11.009
– volume: 6
  start-page: 580
  year: 2009
  ident: ref_81
  article-title: Role of cancer stem cells in pancreatic ductal adenocarcinoma
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/nrclinonc.2009.127
– volume: 16
  start-page: 190
  year: 2018
  ident: ref_49
  article-title: Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer
  publication-title: J. Transl. Med.
  doi: 10.1186/s12967-018-1562-z
– volume: 73
  start-page: 692
  year: 2021
  ident: ref_56
  article-title: C24-Ceramide Drives Gallbladder Cancer Progression Through Directly Targeting Phosphatidylinositol 5-Phosphate 4-Kinase Type-2 Gamma to Facilitate Mammalian Target of Rapamycin Signaling Activation
  publication-title: Hepatology
  doi: 10.1002/hep.31304
– volume: 12
  start-page: 1
  year: 2021
  ident: ref_58
  article-title: BUB1B promotes extrahepatic cholangiocarcinoma progression via JNK/c-Jun pathways
  publication-title: Cell Death Dis.
  doi: 10.1038/s41419-020-03234-x
– volume: 8
  start-page: e000367
  year: 2020
  ident: ref_55
  article-title: Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: Results from a phase II study
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2019-000367
– volume: 6
  start-page: 37606
  year: 2016
  ident: ref_42
  article-title: Quantitative secretomic analysis of pancreatic cancer cells in serum-containing conditioned medium
  publication-title: Sci. Rep.
  doi: 10.1038/srep37606
– volume: 11
  start-page: 1
  year: 2020
  ident: ref_69
  article-title: Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-15979-2
– volume: 3
  start-page: 28
  year: 2010
  ident: ref_11
  article-title: Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer
  publication-title: Am. J. Transl. Res.
– volume: 33
  start-page: 137
  year: 2013
  ident: ref_57
  article-title: Oncogenic potential of Cyclin Kinase Subunit-2 in cholangiocarcinoma
  publication-title: Liver Int.
  doi: 10.1111/liv.12014
– volume: 10
  start-page: 1
  year: 2020
  ident: ref_47
  article-title: Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-020-78320-3
– volume: 7
  start-page: 32100
  year: 2016
  ident: ref_48
  article-title: Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.8527
– volume: 81
  start-page: 277
  year: 2018
  ident: ref_24
  article-title: Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine
  publication-title: Cancer Chemother. Pharmacol.
  doi: 10.1007/s00280-017-3475-6
– volume: 47
  start-page: 1123
  year: 2018
  ident: ref_27
  article-title: Characterization of the Neuroendocrine Tumor Immune Microenvironment
  publication-title: Pancreas
  doi: 10.1097/MPA.0000000000001150
– volume: 9
  start-page: 4678
  year: 2019
  ident: ref_60
  article-title: Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors
  publication-title: Theranostics
  doi: 10.7150/thno.36276
– volume: 113
  start-page: 1467
  year: 2015
  ident: ref_9
  article-title: Plasma microRNA profiles: Identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2015.366
– volume: 8
  start-page: e9736
  year: 2020
  ident: ref_51
  article-title: The nine ADAMs family members serve as potential biomarkers for immune infiltration in pancreatic adenocarcinoma
  publication-title: PeerJ
  doi: 10.7717/peerj.9736
– volume: 29
  start-page: 4741
  year: 2010
  ident: ref_82
  article-title: EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer
  publication-title: Oncogene
  doi: 10.1038/onc.2010.215
– volume: 13
  start-page: 261
  year: 2016
  ident: ref_4
  article-title: Expert consensus document: Cholangiocarcinoma: Current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
  publication-title: Nat. Rev. Gastroenterol. Hepatol.
  doi: 10.1038/nrgastro.2016.51
– volume: 1445
  start-page: 62
  year: 2019
  ident: ref_44
  article-title: Anti-CTLA-4 synergizes with dendritic cell-targeted vaccine to promote IL-3-dependent CD4(+) effector T cell infiltration into murine pancreatic tumors
  publication-title: Ann. N. Y. Acad. Sci.
  doi: 10.1111/nyas.14049
– volume: 4
  start-page: 46
  year: 2016
  ident: ref_62
  article-title: Circulating protein and antibody biomarker for personalized cancer immunotherapy
  publication-title: J. Immunother. Cancer
  doi: 10.1186/s40425-016-0150-0
– volume: 29
  start-page: 4627
  year: 2011
  ident: ref_6
  article-title: Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2010.33.8020
– volume: 366
  start-page: 2455
  year: 2012
  ident: ref_75
  article-title: Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1200694
– volume: 31
  start-page: 745
  year: 2020
  ident: ref_87
  article-title: Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2020.02.011
– volume: 7
  start-page: 428
  year: 2019
  ident: ref_79
  article-title: A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell–Mediated Anticancer Activity
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-18-0061
– volume: 147
  start-page: 517
  year: 2021
  ident: ref_26
  article-title: Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer
  publication-title: J. Cancer Res. Clin. Oncol.
  doi: 10.1007/s00432-020-03463-9
– volume: 8
  start-page: 5986
  year: 2018
  ident: ref_31
  article-title: Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer
  publication-title: Theranostics
  doi: 10.7150/thno.26650
– volume: 78
  start-page: 475
  year: 2017
  ident: ref_72
  article-title: Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-17-2415
– volume: 2020
  start-page: 1
  year: 2020
  ident: ref_12
  article-title: MicroRNA-7 as a Potential Biomarker for Prognosis in Pancreatic Cancer
  publication-title: Dis. Markers
– volume: 4
  start-page: 783
  year: 2012
  ident: ref_20
  article-title: MACC1: A potential molecule associated with pancreatic cancer metastasis and chemoresistance
  publication-title: Oncol. Lett.
  doi: 10.3892/ol.2012.784
– volume: 66
  start-page: 124
  year: 2017
  ident: ref_67
  article-title: Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer
  publication-title: Gut
  doi: 10.1136/gutjnl-2016-312078
– volume: 22
  start-page: 851
  year: 2016
  ident: ref_33
  article-title: Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
  publication-title: Nat. Med.
  doi: 10.1038/nm.4123
– volume: 38
  start-page: 1
  year: 2019
  ident: ref_59
  article-title: MFAP5 facilitates the aggressiveness of intrahepatic Cholangiocarcinoma by activating the Notch1 signaling pathway
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-019-1477-4
– volume: 11
  start-page: eaau9240
  year: 2019
  ident: ref_34
  article-title: Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.aau9240
– volume: 36
  start-page: 382
  year: 2013
  ident: ref_68
  article-title: Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer
  publication-title: J. Immunother.
  doi: 10.1097/CJI.0b013e31829fb7a2
– volume: 78
  start-page: 4253
  year: 2018
  ident: ref_36
  article-title: Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-17-3876
– volume: 129
  start-page: 1401
  year: 2007
  ident: ref_86
  article-title: A mammalian microrna expression atlas based on small rna library sequencing
  publication-title: Cell
  doi: 10.1016/j.cell.2007.04.040
– volume: 7
  start-page: 1
  year: 2017
  ident: ref_14
  article-title: Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-017-06137-8
– volume: 28
  start-page: 2140
  year: 2019
  ident: ref_76
  article-title: Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2019.07.059
– volume: 109
  start-page: djw283
  year: 2017
  ident: ref_35
  article-title: The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/djw283
– volume: 158
  start-page: 881
  year: 2015
  ident: ref_85
  article-title: Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts
  publication-title: Surgery
  doi: 10.1016/j.surg.2015.04.043
– volume: 26
  start-page: 4661
  year: 2020
  ident: ref_21
  article-title: Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-20-0395
– volume: 7
  start-page: 311
  year: 2019
  ident: ref_66
  article-title: Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism
  publication-title: J. Immunother. Cancer
  doi: 10.1186/s40425-019-0786-7
– volume: 245
  start-page: 755
  year: 2007
  ident: ref_8
  article-title: Cholangiocarcinoma: Thirty-one-year experience with 564 patients at a single institution
  publication-title: Ann. Surg.
  doi: 10.1097/01.sla.0000251366.62632.d3
– volume: 9
  start-page: 814
  year: 2018
  ident: ref_43
  article-title: Tribody [(HER2)(2)×CD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2018.00814
– volume: 7
  start-page: 977
  year: 2019
  ident: ref_70
  article-title: Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-18-0448
– volume: 8
  start-page: 7161
  year: 2019
  ident: ref_19
  article-title: MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers
  publication-title: Cancer Med.
  doi: 10.1002/cam4.2583
– volume: 35
  start-page: 133
  year: 2016
  ident: ref_22
  article-title: PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-016-0406-z
– volume: 28
  start-page: 794
  year: 2020
  ident: ref_40
  article-title: Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody
  publication-title: Mol. Ther.
  doi: 10.1016/j.ymthe.2020.01.003
– volume: 18
  start-page: 1
  year: 2018
  ident: ref_15
  article-title: An elevated expression of serum exosomal microRNA-191, -21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker
  publication-title: BMC Cancer
  doi: 10.1186/s12885-018-4006-5
– volume: 8
  start-page: 606817
  year: 2020
  ident: ref_16
  article-title: A Novel Autophagy-Related IncRNAs Signature for Prognostic Prediction and Clinical Value in Patients With Pancreatic Cancer
  publication-title: Front. Cell Dev. Biol.
  doi: 10.3389/fcell.2020.606817
– volume: 9
  start-page: eaak9679
  year: 2017
  ident: ref_80
  article-title: Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.aak9679
– volume: 36
  start-page: 6143
  year: 2017
  ident: ref_54
  article-title: Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers
  publication-title: Oncogene
  doi: 10.1038/onc.2017.209
– volume: 7
  start-page: 77
  year: 2019
  ident: ref_53
  article-title: HHLA2 in intrahepatic cholangiocarcinoma: An immune checkpoint with prognostic significance and wider expression compared with PD-L1
  publication-title: J. Immunother. Cancer
  doi: 10.1186/s40425-019-0554-8
– volume: 69
  start-page: 1951
  year: 2009
  ident: ref_83
  article-title: Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-i receptor inhibition
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-08-2023
– volume: 84
  start-page: 38
  year: 2017
  ident: ref_13
  article-title: The Clinical Significance of miR-34a in Pancreatic Ductal Carcinoma and Associated Molecular and Cellular Mechanisms
  publication-title: Pathobiology
  doi: 10.1159/000447302
– volume: 76
  start-page: 6851
  year: 2016
  ident: ref_23
  article-title: Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-16-1201
– volume: 33
  start-page: 828
  year: 2010
  ident: ref_74
  article-title: Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
  publication-title: J. Immunother.
  doi: 10.1097/CJI.0b013e3181eec14c
– volume: 13
  start-page: 74
  year: 2016
  ident: ref_2
  article-title: Pancreatic cancer in 2015: Precision medicine in pancreatic cancer—Fact or fiction?
  publication-title: Nat. Rev. Gastroen-terol. Hepatol.
  doi: 10.1038/nrgastro.2015.215
– volume: 12
  start-page: 1
  year: 2019
  ident: ref_32
  article-title: Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-019-0822-6
– volume: 39
  start-page: 3102
  year: 2020
  ident: ref_63
  article-title: Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels
  publication-title: Oncogene
  doi: 10.1038/s41388-020-1186-7
– volume: 319
  start-page: 6
  year: 2012
  ident: ref_45
  article-title: Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma
  publication-title: Cancer Lett.
– ident: ref_77
  doi: 10.3390/cells8040320
– volume: 48
  start-page: 466
  year: 2019
  ident: ref_39
  article-title: Prognostic Values of CD38(+)CD101(+)PD1(+)CD8(+) T Cells in Pancreatic Cancer
  publication-title: Immunol. Investig.
  doi: 10.1080/08820139.2019.1566356
– volume: 68
  start-page: 1635
  year: 2019
  ident: ref_41
  article-title: Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tu-mor microenvironment
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-019-02398-6
– volume: 11
  start-page: 770
  year: 2020
  ident: ref_3
  article-title: A review of systemic therapy in biliary tract carcinoma
  publication-title: J. Gastrointest. Oncol.
  doi: 10.21037/jgo-20-203
– volume: 31
  start-page: 1188
  year: 2013
  ident: ref_5
  article-title: Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2012.41.5984
SSID ssj0000331767
Score 2.2494242
SecondaryResourceType review_article
Snippet Background: pancreatic cancer (PCa) and biliary tract cancer (BTC) are cancers with a poor prognosis and few effective treatments. One of the reasons for this...
Simple SummaryPancreatic and biliary tract cancers are malignant tumors that have a very poor prognosis and are resistant to chemotherapy. The later a cancer...
pancreatic cancer (PCa) and biliary tract cancer (BTC) are cancers with a poor prognosis and few effective treatments. One of the reasons for this is late...
SourceID pubmedcentral
proquest
crossref
SourceType Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 4220
SubjectTerms Antigens
Biliary tract
Biomarkers
Cancer therapies
Chemotherapy
Cholangiocarcinoma
Diagnosis
Fibroblasts
Lymphocytes
Medical prognosis
Metastasis
MicroRNAs
Neuroendocrine tumors
Pancreatic cancer
Plasma
Prognosis
Protein expression
Proteins
Review
Systematic review
Tumors
SummonAdditionalLinks – databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfZ1fi9NAEMAX6YH4InenYs_eMYIPvqSa7L9GkKOtliJUBFvoW8huNhqoyZm0cP0GfmxnkrS1Ug3kaXfZZGd35zfs7AxjrwKZhCZVnEIhak8kg9CLdZp40vmxtT5dXKbLybPParoQn5ZyeUgH1A5gddK0o3xSi3LVv_-5vcUF_54sTjTZ31gan7LyOaJ_EKD9foZqSdEUn7WsX2_LHFWl0k14n1PtjjXTATePnSX_0D6Tc_a4xUYYNnK-YA9cfskeztqD8Sfs13iXFKUCxFAY1bd04EPjSJdVEOcJHFxdoEjhC35XTYy2LhxlqywutzCna1Mwbj4aJoUlz_hvUOQwIh93rFf8IJeesnoHQ_i6DwQNzSnDU7aYfJyPp16bZMGzQom1h39ulUDsQMWfGimM9F2t5qU1WqhBYLngKjH0Iipwx42UXNhQOjSWjODPWCcvcvecgRTa6sCFvjFWhAbZMZBmYEXqEJtUEnRZfzfAkW0jkFMijFWElghJJPpLIl32et_grgm-8e-qvZ3Eot0kihDnhMZnoLvs5b4Y1w8disS5KzZ1HYVYi5tRl-kjSe-7pAjcxyV59r2OxI10KRBwrv7f-Qv2KCBPmLe4J_Ee66zLjbtGlFmbm3qK_gY9M_Ys
  priority: 102
  providerName: Scholars Portal
Title Challenges for Better Diagnosis and Management of Pancreatic and Biliary Tract Cancers Focusing on Blood Biomarkers: A Systematic Review
URI https://www.proquest.com/docview/2564777787
https://www.proquest.com/docview/2566045005
https://pubmed.ncbi.nlm.nih.gov/PMC8394661
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEB6aDZReSh4t3eaBAj304iS2XnYuIbvNNhQ2hDxgb8aS5XQhtZP15tB_0J-dGVvrzRZag32RjGWNNPON5gXwJZJ5YgrFKRWiDkQeJ0GmizyQLsysDSlwmYKTx5fq4k78mMiJP3CrvVvlgic2jDqvLJ2RH6FoFhqvWJ8-PgVUNYqsq76ExhqsIwuOZQ_WB-eXV9fdKcsxR_modJvTh6N-f2RpMmd1yFFPiKjK92txtMSYqx6Sr0TOaAPee6zIzlribsIbV27B27G3hm_Dn-GiEkrNEHuyQROaw7613nPTmmVlzpb-Lawq2BWOq4GJtmkcTB-m2ew3u6VYKTZsB81GlSV3-HtWlWxAju3Yr_pFfjyz-oSdsZsu-zNrTQsf4G50fju8CHxlhcAKJeYB_rlVArEGSvvCSGFk6BrZLq3RQsWR5YKr3NCN-IA7bqTkwibSoYZkBP8IvbIq3SdgUmirI5eExliRGASMkTSxFYVDrKTyqA-HiwlOrU87TtUvHlJUP4gi6V8U6cPX7oXHNuPGv7vuLiiW-q1Xp8uF0oeDrhk3DVlCstJVz00fhVgWOVAf9Aqlu09S2u3VlnL6s0m_jZBSIKr5_P-P78C7iNxfjpER8V3ozWfPbg_xy9zs-0W6D2vfJyE-xyJ-AVdh9ZQ
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTQJeEJ-ibICRQOIlrPFH3ExCaO1WdWytJuikvYXYcaDSloym07T_gL-Gv5G7fHVFgrdFypOd2PL57n5n3wfAW66S0KSBoFSI2pNJL_RinSaecn5srU-ByxScPJ4EoxP5-VSdrsHvJhaG3CobmVgK6iS3dEa-japZanx6-tPFT4-qRtHtalNCo9oWh-76Ck224uPBHtL3HefD_elg5NVVBTwrA7nwJOc2kKhnUdOlRkmjfFfqNWWNlkGPWyFFkBh6UTcKJ4xSQtpQObQOjBT43zuwgTAjRC7a6O9Pjr-0pzpdgfo40FUOISHC7rYl4s0LX6Bdwqmq-E31t8S0qx6ZN1Tc8CE8qLEp26020yNYc9ljuDuub9-fwK9BU3mlYIh1Wb8MBWJ7lbferGBxlrClPw3LU3aM8yphqS0b-7OzWTy_ZlOKzWKDatJsmFtyv__O8oz1yZEe--Xn5Dc0L3bYLvvaZptm1VXGUzi5lTV_ButZnrnnwJTUVnMX-sZYGRoEqFyZnpWpQ2wWJLwDH5oFjmyd5pyqbZxFaO4QRaK_KNKB9-0HF1WGj3933WooFtWsXkTLjdmBN20zMindvMSZyy_LPgFiZ5R4HdArlG6HpDTfqy3Z7EeZ7hshrEQU9eL_g7-Ge6Pp-Cg6OpgcbsJ9Tq43XRSCYgvWF_NL9xKx08K8qjcsg2-3zSN_AIRcLds
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1tb9MwED6NTpr4gngVZQOMBBJfQhu_xA0SQmu7amOsqmCT9i2LHQcqbcloOqH9A34Tv467vHVFgm-LlE-2E8tn-56zn7sDeM1VEpo0EBQKUXsyGYRerNPEU86PrfXJcZmck4-mwf6J_HSqTjfgd-MLQ7TKZk8sN-okt3RG3kPVLDU-A91La1rEbDz5ePnDowxSdNPapNOopsihu_6J5lvx4WCMsn7D-WTveLTv1RkGPCsDufQk5zaQqHNR66VGSaN8V-o4ZY2WwYBbIUWQGHpRTwonjFJC2lA5tBSMFPjdO7CpscWgA5vDvensS3vC0xeomwNdxRMSIuz3LAlyUfgCbRROGcZvqsIVvl1nZ95Qd5P7cK_GqWy3mlgPYMNlD2HrqL6JfwS_Rk0WloIh7mXD0i2IjSvm3rxgcZawFbeG5SmbYb9KiGrLwuH8fB4vrtkx-WmxUdVpNsktUfG_sTxjQyLVY738gjhEi-I922Vf28jTrLrWeAwntzLmT6CT5Zl7CkxJbTV3oW-MlaFBsMqVGViZOsRpQcK78K4Z4MjWIc8p88Z5hKYPSST6SyJdeNs2uKyiffy76k4jsahe9kW0mqRdeNUW44KlW5g4c_lVWSdAHI27Xxf0mqTbX1LI7_WSbP69DP2NcFYionr2_5-_hC1cG9Hng-nhNtzlxMLp434odqCzXFy55wijluZFPV8ZnN32EvkDQZUyBw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Challenges+for+Better+Diagnosis+and+Management+of+Pancreatic+and+Biliary+Tract+Cancers+Focusing+on+Blood+Biomarkers%3A+A+Systematic+Review&rft.jtitle=Cancers&rft.au=Tominaga%2C+Hiroto&rft.au=Matsuzaki%2C+Juntaro&rft.au=Oikawa%2C+Chihiro&rft.au=Toyoshima%2C+Kensho&rft.date=2021-08-23&rft.pub=MDPI+AG&rft.eissn=2072-6694&rft.volume=13&rft.issue=16&rft.spage=4220&rft_id=info:doi/10.3390%2Fcancers13164220&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon